Recently, Guangdong Yifang Pharmaceutical Co., Ltd. (hereinafter referred to as Yifang Pharmaceutical) received a drug registration approval document issued by the Ministry of Health and Prevention (MOH) of the United Arab Emirates (hereinafter referred to as the UAE), approving that the Huashibaidu granules produced by Yifang Pharmaceutical meet the UAE The emergency product standard registration of botanical medicines marks the official entry of Huashibaidu Granules into the UAE market as a medicine. It not only has a positive impact on Yifang Pharmaceutical’s expansion of overseas markets, but also signifies that China’s “Chinese medicine power” has gained in the global fight against the epidemic. Recognize and play an increasingly important role.
Huashibaidu Granules is based on the first batch of national TCM medical teams established by the Chinese Academy of Chinese Medical Sciences to go to Wuhan to carry out the treatment of patients with new coronary pneumonia, inherit the theories and experience of TCM prevention and treatment of infectious diseases, and treat them, summarize them, and research and develop them. It is China’s first innovative Chinese medicine for the treatment of new coronary pneumonia with completely independent intellectual property rights, and also China’s first innovative Chinese medicine for the treatment of new coronary pneumonia with clinical approval. It is the materialization of the theory and clinical curative effect of Chinese medicine on the epidemic. The carrier is China's most cutting-edge innovative scientific research results in the clinical treatment of new coronary pneumonia.
The State Administration of Traditional Chinese Medicine listed Huashibaidu Granules as one of the "three medicines and three prescriptions" of effective prescriptions for the treatment of new coronary pneumonia, and was included in the fifth, sixth and seventh editions of the National Guidelines for the Diagnosis and Treatment of New Coronavirus Pneumonia.
After the approval of the clinical trial of Huashibaidu Granules, the Chinese Academy of Chinese Medical Sciences and the medical teams of Zhongnan Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Changchun University of Traditional Chinese Medicine and other units completed the clinical trial research.
Huashibaidu Granules has realized the transformation from clinical practice to scientific research data and then to new drugs. Only by industrializing its production can it truly realize the transformation of scientific and technological achievements and promote the distribution of my country’s original drug intellectual property rights; it can promote Chinese medicine to go global and benefit more people.
On March 30, Guangdong Yifang Pharmaceutical Co., Ltd., a subsidiary of China Traditional Chinese Medicine (HK.00570), signed the "Technology Transfer Contract" with the China Academy of Chinese Medical Sciences. The China Academy of Chinese Medical Sciences transferred the clinical trial approval, patent and drug registration certificate of Huashibaidu Granules Yifang Pharmaceutical.
The transfer funds will be used for the training of Chinese medicine talents, and the establishment of the “China Academy of Chinese Medical Sciences Talent Training Program” will encourage more people to learn Chinese medicine, cultivate and select high-quality Chinese medicine talents, and build a foundation for the inheritance and development of Chinese medicine.
For example, support the children of the members of the Hubei anti-epidemic Chinese medicine medical team to learn Chinese medicine, and support the establishment of the Chinese Academy of Chinese Medical Sciences.
During the epidemic, traditional Chinese medicines represented by Huashibaidu granules were used for the prevention and treatment of new coronary pneumonia overseas, which caused widespread concern. In the UAE, Huashibaidu Granules have been recognized by the local royal family, high-level government and health authorities, and Chinese R&D personnel are specially invited to hold seminars to gain insights into the principles of Huashibaidu Granules formulation, clinical efficacy and drug safety test results In the end, the UAE approved the listing of Huashibaidu Granules as emergency registration drugs.